PMID- 34448208
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 96
IP  - 2
DP  - 2022 Feb
TI  - The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and 
      glycaemic control in Prader-Willi syndrome: A systematic review.
PG  - 144-154
LID - 10.1111/cen.14583 [doi]
AB  - OBJECTIVE: The mainstay management of hyperphagia and obesity in Prader-Willi 
      syndrome (PWS) relies on dietary restrictions, strict supervision and behavioural 
      modifications, which can be stressful for the patient and caregiver. There is no 
      established pharmacological strategy to manage this aspect of PWS. Theoretically, 
      glucagon-like peptide-1 (GLP-1) receptor agonists (GLP1-RA) used in patients with 
      obesity and type 2 diabetes mellitus (T2DM) may be efficacious in weight and 
      glycaemic control of PWS patients. We conducted a systematic review of the 
      literature to summarize the evidence on the use of GLP1-RA in PWS patients. 
      DESIGN: Primary studies were searched in major databases using key concepts 
      'Prader-Willi syndrome' and 'GLP1 receptor agonist' and outcomes, 'weight control 
      OR glycaemic control OR appetite regulation'. RESULTS: Ten studies included, 
      summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used 
      either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 
      years. Sixteen (70%) of these patients had T2DM. Ten patients experienced 
      improvement in body mass index, ranging from 1.5 to 16.0 kg/m(2) , while 
      improvement in HbA1c was seen in 19 of 23 cases, ranging between 0.3% and 7.5%. 
      All five studies reporting appetite or satiety showed improvement in satiety 
      levels. There were no reported serious side effects. CONCLUSIONS: GLP1-RA appears 
      safe in PWS patients and may have potential benefits for weight, glycaemic and 
      appetite control. Nonetheless, we also highlight a significant gap in the 
      literature on the lack of well-designed studies in this area, which limits the 
      recommendation of GLP1-RA use in PWS patients at present.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Ng, Nicholas Beng Hui
AU  - Ng NBH
AUID- ORCID: 0000-0002-7948-8891
AD  - Department of Paediatrics, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
FAU - Low, Yue Wey
AU  - Low YW
AD  - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 
      Singapore.
FAU - Rajgor, Dimple Dayaram
AU  - Rajgor DD
AD  - Department of Paediatrics, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
AD  - Department of Paediatrics, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
FAU - Low, Jia Ming
AU  - Low JM
AD  - Department of Neonatology, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
FAU - Lim, Yvonne Yijuan
AU  - Lim YY
AD  - Department of Paediatrics, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
FAU - Loke, Kah Yin
AU  - Loke KY
AD  - Department of Paediatrics, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
AD  - Department of Paediatrics, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
FAU - Lee, Yung Seng
AU  - Lee YS
AUID- ORCID: 0000-0002-1253-0557
AD  - Department of Paediatrics, Khoo Teck Puat-National University Children's Medical 
      Institute, National University Hospital, Singapore, Singapore.
AD  - Department of Paediatrics, Yong Loo Lin School of Medicine, National University 
      of Singapore, Singapore, Singapore.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20210826
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucagon-Like Peptide 1
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Glycemic Control
MH  - Humans
MH  - Liraglutide/therapeutic use
MH  - *Prader-Willi Syndrome/drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - Prader-Willi syndrome
OT  - diabetes mellitus
OT  - exenatide
OT  - glucagon-like peptide 1 receptor agonists
OT  - hyperphagia
OT  - liraglutide
OT  - obesity
EDAT- 2021/08/28 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/08/27 07:09
PHST- 2021/08/05 00:00 [revised]
PHST- 2021/06/27 00:00 [received]
PHST- 2021/08/17 00:00 [accepted]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/08/27 07:09 [entrez]
AID - 10.1111/cen.14583 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2022 Feb;96(2):144-154. doi: 10.1111/cen.14583. Epub 2021 
      Aug 26.